PREDICTIVE VALUE OF IMMUNOHISTOCHEMICAL BIOMARKERS IN THE DIFFERENTIAL DIAGNOSIS OF BENIGN, BORDERLINE, AND MALIGNANT OVARIAN CYSTIC TUMORS
Keywords:
ovarian cystic tumors, ovarian cancer, borderline ovarian tumor, immunohistochemistry, Ki-67, p53, WT1, PAX8, malignant potential.Abstract
Background. Differential diagnosis of ovarian cystic tumors remains an important problem in gynecologic oncology. Although histopathological examination is the basis of definitive diagnosis, some benign, borderline, and malignant ovarian tumors demonstrate overlapping morphological features. Immunohistochemical biomarkers may provide additional information regarding cellular proliferation, tumor differentiation, molecular alterations, and biological aggressiveness.
Objective. To evaluate the diagnostic and potential prognostic significance of selected immunohistochemical biomarkers in differentiating benign, borderline, and malignant ovarian cystic tumors.
Materials and Methods. The study analyzed contemporary evidence concerning the expression of p53, Ki-67, WT1, PAX8, p16, estrogen receptor (ER), progesterone receptor (PR), Napsin A, and mismatch-repair proteins in epithelial ovarian tumors. Particular attention was paid to differences in immunohistochemical profiles among benign cystadenomas, borderline tumors, and invasive ovarian carcinomas and to the relationship between biomarker expression and histological subtype.
Results. Increasing proliferative activity assessed by Ki-67 is generally associated with progression from benign lesions toward malignant tumors, although considerable variation exists among histological subtypes. Abnormal p53 expression is strongly associated with high-grade serous carcinoma. WT1 and PAX8 are useful in confirming Müllerian and serous differentiation. Napsin A may support clear-cell differentiation, while ER and PR contribute to the characterization of serous and endometrioid tumors. Assessment of mismatch-repair proteins may identify a subgroup of tumors with potential hereditary and therapeutic significance. The greatest diagnostic value is achieved when immunohistochemical findings are interpreted in combination with tumor morphology rather than as isolated markers.
Conclusion. Immunohistochemical profiling represents a valuable complementary method for differential diagnosis of ovarian cystic tumors. A combined panel incorporating proliferative, tumor-suppressor, differentiation, and molecular-surrogate markers may improve discrimination among benign, borderline, and malignant lesions and facilitate individualized oncological management.
References
1.WHO Classification of Tumours Editorial Board. Female Genital Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2020.
2.Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–747.
3.Prat J, D'Angelo E, Espinosa I. Ovarian




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal